MX2022008727A - Factor de crecimiento derivado de mieloide para su uso en el tratamiento o la prevencion de fibrosis, hipertrofia o insuficiencia cardiaca. - Google Patents

Factor de crecimiento derivado de mieloide para su uso en el tratamiento o la prevencion de fibrosis, hipertrofia o insuficiencia cardiaca.

Info

Publication number
MX2022008727A
MX2022008727A MX2022008727A MX2022008727A MX2022008727A MX 2022008727 A MX2022008727 A MX 2022008727A MX 2022008727 A MX2022008727 A MX 2022008727A MX 2022008727 A MX2022008727 A MX 2022008727A MX 2022008727 A MX2022008727 A MX 2022008727A
Authority
MX
Mexico
Prior art keywords
treating
hypertrophy
heart failure
myeloid
growth factor
Prior art date
Application number
MX2022008727A
Other languages
English (en)
Spanish (es)
Inventor
Kai Christoph Wollert
Mortimer Korf-Klingebiel
Marc R Reboll
Anton Pekcec
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2022008727A publication Critical patent/MX2022008727A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2022008727A 2020-01-21 2021-01-19 Factor de crecimiento derivado de mieloide para su uso en el tratamiento o la prevencion de fibrosis, hipertrofia o insuficiencia cardiaca. MX2022008727A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20153008 2020-01-21
PCT/EP2021/051079 WO2021148411A1 (en) 2020-01-21 2021-01-19 Myeloid-derived growth factor for use in treating or preventing fibrosis, hypertrophy or heart failure

Publications (1)

Publication Number Publication Date
MX2022008727A true MX2022008727A (es) 2022-10-07

Family

ID=69187588

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022008727A MX2022008727A (es) 2020-01-21 2021-01-19 Factor de crecimiento derivado de mieloide para su uso en el tratamiento o la prevencion de fibrosis, hipertrofia o insuficiencia cardiaca.

Country Status (12)

Country Link
US (1) US20230059560A1 (https=)
EP (1) EP4093750A1 (https=)
JP (1) JP7777532B2 (https=)
KR (1) KR20220131262A (https=)
CN (1) CN115698048A (https=)
AU (1) AU2021211874A1 (https=)
BR (1) BR112022014272A2 (https=)
CA (2) CA3164500A1 (https=)
MX (1) MX2022008727A (https=)
PH (1) PH12022551792A1 (https=)
TW (1) TW202142254A (https=)
WO (1) WO2021148411A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022066729A1 (en) * 2020-09-22 2022-03-31 Wisconsin Alumni Research Foundation Method to inhibit neutrophil recruitment to damaged tissue using myeloid-derived growth factor
US20250325704A1 (en) 2020-12-23 2025-10-23 Boehringer Ingelheim International Gmbh Viral capsid proteins with specificity to heart tissue cells
CN115820829B (zh) * 2022-03-22 2026-04-17 中国人民解放军军事科学院军事医学研究院 Mydgf在防治记忆损伤及其相关疾病中的应用
JP2025518285A (ja) 2022-06-03 2025-06-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 骨髄由来増殖因子の組換え発現
JP2025530232A (ja) 2022-09-08 2025-09-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 心原性ショックの処置に用いる骨髄由来成長因子
EP4480490A1 (en) * 2023-06-23 2024-12-25 Medizinische Hochschule Hannover Brick1 for use in treating myocardial diseases
WO2025073372A1 (en) 2023-10-05 2025-04-10 Boehringer Ingelheim International Gmbh Recombinant expression of myeloid-derived growth factor
TW202539726A (zh) 2023-12-06 2025-10-16 德商百靈佳殷格翰國際股份有限公司 包含骨髓衍生性生長因子之新穎調配物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
AU717542B2 (en) 1996-06-11 2000-03-30 Merck & Co., Inc. Synthetic hepatitis C genes
WO1998011217A2 (en) * 1996-09-13 1998-03-19 Sagami Chemical Research Center HUMAN PROTEINS HAVING SECRETORY SIGNAL SEQUENCES AND DNAs ENCODING THESE PROTEINS
JP2001506484A (ja) 1996-09-13 2001-05-22 財団法人相模中央化学研究所 分泌シグナル配列を有するヒト蛋白質およびそれをコードするｄｎａ
CA2503390A1 (en) 2002-11-01 2004-05-21 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2004069173A2 (en) 2003-01-31 2004-08-19 The Trustees Of The University Of Pennsylvania Methods for modulating an inflammatory response
US20080004232A1 (en) 2006-05-09 2008-01-03 John Wilkins Characterization of c19orf10, a Novel Synovial Protein
EP2130547A1 (en) 2008-06-06 2009-12-09 Giuliani International Limited IL-25 for use in the treatment of inflammatory diseases
DK2945642T3 (da) * 2013-01-17 2024-05-27 Medizinische Hochschule Hannover Faktor 1 protein til anvendelse i behandling eller forebyggelse af sygdomme
JP7405772B2 (ja) * 2018-05-09 2023-12-26 ケロス セラピューティクス インコーポレイテッド アクチビンｉｉａ型受容体変異体および同変異体を含む医薬組成物
WO2020176732A1 (en) * 2019-02-27 2020-09-03 Icahn School Of Medicine At Mount Sinai TREATMENT OF PULMONARY FIBROSIS WITH SERCA2a GENE THERAPY

Also Published As

Publication number Publication date
PH12022551792A1 (en) 2023-09-18
EP4093750A1 (en) 2022-11-30
CA3164500A1 (en) 2021-07-29
AU2021211874A1 (en) 2022-08-25
WO2021148411A1 (en) 2021-07-29
JP7777532B2 (ja) 2025-11-28
KR20220131262A (ko) 2022-09-27
TW202142254A (zh) 2021-11-16
JP2023511358A (ja) 2023-03-17
CN115698048A (zh) 2023-02-03
US20230059560A1 (en) 2023-02-23
CA3223879A1 (en) 2021-07-29
BR112022014272A2 (pt) 2022-09-20

Similar Documents

Publication Publication Date Title
PH12022551792A1 (en) Myeloid-derived growth factor for use in treating or preventing fibrosis, hypertrophy or heart failure
MX2022005236A (es) Composiciones y metodos para el tratamiento de la perdida auditiva neurosensorial mediante el uso de sistemas de vectores duales de otoferlina.
PH12020551957A1 (en) Codon-optimized acid alpha-glucosidase expression cassettes and methods of using same
MX2016005101A (es) Factor de crecimiento de fibroblastos (fgf) 1 mutado y procedimientos de uso.
SA519401442B1 (ar) إنزيمات تعديل حمض نووي موجه بالحمض النووي الريبوزي وطرق استخدامها
WO2016048995A3 (en) Fgf19 truncations and mutants and uses thereof
MX2020006424A (es) Polipéptidos de dominio de unión a células de toxina botulínica y métodos de uso para el rejuvenecimiento de la piel.
WO2016172156A3 (en) Fibroblast growth factor (fgf) 1 mutants and methods of use to reduce blood glucose
GB2569733A (en) RNA-guided nucleic acid modifying enzymes and methods of use thereof
ATE352626T1 (de) Polypeptide mit galaktoseoxidaseaktivität und dafür kodierende nukleisäuren
NZ595500A (en) Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them
WO2016172153A3 (en) Fibroblast growth factor (fgf) 1 with mutation in the heparin binding domain and methods of use to reduce blood glucose
MX2020005724A (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
MX2022010050A (es) Composiciones y metodos para tratar deficiencia auditiva no asociada con la edad en un sujeto humano.
WO2020186207A8 (en) Non-viral dna vectors and uses thereof for expressing fviii therapeutics
ATE450603T1 (de) Polypeptide mit verzweigungsenzym-aktivität und für diese kodierende nukleinsäuren
FR2862312B1 (fr) Outil de transfert et de production de proteines mettant en oeuvre le systeme de secretion de type iii de pseudomonas
DE60036537D1 (de) Zusammensetzungen zur gentherapie von diabetes
WO2022235933A8 (en) Compositions and methods for treating sensorineural hearing loss using stereocilin dual vector systems
SA523451188B1 (ar) شظية ربط مولد الضد مضادة لـليمفوبويتين الغدة الصعترية ذو ثبات محسن
AR051837A1 (es) Produccion de proteinas de fusion recombinante dentro de ensamblajes similares a cuerpos proteicos recombinantes (escpr)
ATE377649T1 (de) Verfahren und zelle zur expression von rekombinanten proteinprodukten
WO2020210480A3 (en) Factor h vectors and uses thereof
MX2025002493A (es) Factor de crecimiento derivado de mieloides para su uso en el tratamiento del shock cardiogenico
DOP2025000239A (es) Compuestos y métodos para reducir la expresión de pln